Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.

CNS oncology - 1 Dec 2026

Evans Dylan, Voisey Joanne, Gunter Jennifer H, Rae Fiona

Abstract excerpt

INTRODUCTION: Glioblastoma (GBM) is the most aggressive and biologically heterogeneous tumor of the central nervous system, associated with dismal prognosis and frequent recurrence. Amplification of the epidermal growth factor receptor (EGFR) and EGFRvIII mutation are common alterations, yet their prognostic significance remains unclear. This systematic review evaluated whether clinical evidence supports a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to ErbB Receptors
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Predictive Value of Tests

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 42283227
DOI: 10.1080/20450907.2026.2685339
PMCID: PMC13271296

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.PMID 42283227Read ↗

Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors.Semantic proximity Read ↗

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomasSemantic proximity Read ↗

Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII MutationSemantic proximity Read ↗

EGFR as a clinical marker in glioblastomas and other gliomas.Semantic proximity Read ↗

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.Semantic proximity Read ↗

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Semantic proximity Read ↗

Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.Semantic proximity Read ↗

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisSemantic proximity Read ↗

Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological featuresSemantic proximity Read ↗

Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with GlioblastomaSemantic proximity Read ↗

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.Semantic proximity Read ↗

Integrated longitudinal analysis of glioblastomas with long-term relapse interval revealed upregulation of the Tumor Growth Factor β signaling pathway in the recurrent tumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.